Rx Exclusivity Provisions In 21st Century Cures Expected To Spur Controversy
This article was originally published in The Pink Sheet Daily
Executive Summary
Legislators tell BIO CEO & Investor Conference there will be difference of opinion on issues like exclusivity, but say there is still strong bipartisan cooperation on developing the House’s drug discovery and development legislation.